McKinsey January 9, 2025
A modern, well-designed tech stack can unlock the potential of AI, automation, and data and their promised benefits to R&D productivity.
Amid growing complexities, escalating costs, and a heightened demand for innovative therapies, biopharmaceutical R&D organizations are under pressure to find ways to boost their productivity. Preclinical studies are increasingly using diverse assays, complex “omics” data, and humanized models to evaluate drug candidates. Clinical trials are adopting new trial designs and incorporating personalized-medicine approaches and even more end points.
In this challenging environment, pharma leaders are turning to advanced technologies such as digital and analytics (DnA) solutions to reshape R&D operations and deliver new efficiencies, such as faster discovery of new molecular entities and novel therapeutic mechanisms. Leading companies are...
Today's Sponsors
Today's Sponsor